Thelansis

  Synovial sarcoma (SYN) is a soft tissue sarcoma, constituting about 5-14% of all soft tissue sarcomas. It typically manifests between the ages of 35 and 40, affecting both males and females equally. While SYN commonly originates in the deep tissues of the extremities, it can also occur in the head, neck, trunk, and lungs. With a historical five-year metastasis-free survival rate of 50-60%, SYN exhibits a high propensity for metastasis. First-line treatment for locally advanced or metastatic SYN typically involves anthracycline-based chemotherapy, with or without ifosfamide. SYN tumors are relatively responsive to chemotherapy compared to other soft tissue sarcomas. Currently, the standard approach for advanced synovial sarcoma involves anthracycline-based chemotherapy. Another FDA-approved systemic therapy for advanced or metastatic SYN is pazopanib. In the United States, SYN has an approximate incidence of 1.42 cases per million among adults and 0.81 cases per mill...